Autres langues Alzinova AB

Actions

ALZ

SE0007413455

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Stockholm 18:00:00 30/09/2026			Varia. 5j.	Varia. 1 janv.
0,4190 ^SEK	+1,21%		+4,23%	-49,46%

11:54	Alzinova achève une étude sur la maladie d’Alzheimer avec Amsterdam UMC	FW
24/09	L’étude de phase II d’Alzinova présentée lors d’un congrès consacré à la maladie d’Alzheimer	FW

Autres langues

11:49	Alzinova : completes study with Amsterdam UMC - results support continued development and partnership discussions in blood-based Alzheimer's diagnostics
11:46	Alzinova completes study with Amsterdam UMC – results support continued development and partnership discussions in blood-based Alzheimer’s diagnostics
24/09	Alzinova’s Phase II study with ALZ-101 accepted for presentation at international Alzheimer’s conference
22/09	The subscription period in Alzinovas rights issue of units starts today
21/09	Alzinova Initiates Global Phase Ii Start-Up of Therapeutic Vaccine Alz-101 and Advances Blood-Based Diagnostic Program
21/09	Alzinova Advances Dual Approach to Alzheimer’s Treatment and Diagnosis as World Alzheimer’s Day Highlights Unmet Need
18/09	Alzinova publishes information memorandum in connection with rights issue of units
11/09	Alzinova: Phase II study update and SEK51 rights issue
11/09	Alzinova: ALZ-101 enters Phase II start-up as Alzinova raises capital
11/09	Alzinova Resolves On Rights Issue Of SEK 51 Mln
11/09	Alzinova Starts Preparations for Mid-stage Trial of Alzheimer's Disease Vaccine Candidate
10/09	The Board of Directors of Alzinova resolves on a rights issue of units of approximately SEK 51 million
10/09	Alzinova initiates operational start-up of global Phase 2 study with ALZ-101
10/09	Alzinova AB Initiates Operational Start-Up Of Global Phase 2 Study With ALZ-101
24/08	Alzinova: Diagnostics readout next, partner process delayed – Q2 review
20/08	Alzinova (Q2 Review): Capitalizing on diagnostics opportunities
20/08	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
20/08	Alzinova publishes interim report for the period January - June 2026
07/07	BioVal™ analysis of Alzinova's ALZ-101 – rNPV of SEK 7.1B
24/06	Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds
24/06	Alzinova AB and Fujirebio Enter Letter of Intent for Potential Commercialization of Blood-Based Alzheimer?S Diagnostic Test
24/06	Alzinova Inks Nonbinding Deal with Fujirebio for Potential Alzheimer's Blood-based Diagnostic Test
24/06	Alzinova signs Letter of Intent with Fujirebio regarding potential commercialization of blood-based Alzheimer’s diagnostic test
12/06	Warrants of series TO4 were exercised to approximately 94.2 percent and the Company will receive approximately 15.3 million
08/06	Alzinova announces preliminary outcome of the exercise of warrants of series TO4